Aetna Inc. (AET), Auxilium Pharmaceuticals, Inc. (AUXL), and ArthroCare Corporation (ARTC): 3 Healthcare Stocks to Avoid

Insiders have information about a company which is not available to outside investors. On the other hand, institutional investors have a lot of resources at their disposal to better assess a stock, something which is not possible for retail investors. The companies listed below have witnessed heavy selling by institutional investors and insiders, which is a strong sell indicator.

Aetna Inc.Aetna Inc. (NYSE:AET) is a diversified health care benefits company with operations in the United States. The company has three basic segments which are Large Case Pensions, Group Insurance, and Health Care. The Health Care segment focuses on providing various plans on insured basis, employer-funded, or administrative basis. The Group Insurance Segment offers insurance products for voluntary spouse, dependent life insurance, and group term life insurance. Various retirement products and plans are managed by the Large Case Pension Segment.

The entire healthcare plans industry has been on a high of late due to good news on Medicare reimbursement rates. The Center for Medicare and Medicaid services has recently increased the reimbursement rates for healthcare plan providers by 3.3%. The stock has responded positively to this news and appreciated 5% in April. In the last one year, Aetna Inc. (NYSE:AET) has appreciated 15%, which is not bad by industry standards.

Despite these positives and overall positive momentum of the stock, there has been some heavy selling by institutions and insiders. In the last six months, institutions have sold a total of 24 million shares of the company, reducing their total holdings by around 8.4%. During the same period, insiders have reduced their own holdings by a mammoth 23%. At current valuations, Aetna Inc. (NYSE:AET) is trading pretty close to its mean sell side target price of $57, and has limited upside potential for investors.

Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) is a biopharmaceutical company which commercializes specialty pharmaceutical products. Its primary products include Testim for hypogonadism and XIAFLEX for Dupuytren. The company is also undertaking Phase III trial for the treatment of Peyronie with XIAFLEX.

In the last one year, shares of Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) have depreciated approximately 11% due to fears of generic competition and the company’s inability to grow its XIAFLEX franchise. These factors have also contributed to institutional investors losing confidence in the company. In the last six months, institutions have sold approximately 7.9 million shares, reducing their total holdings by a significant 20%. During the same period, insiders have added only 56,000 shares to their holdings, an increase of 0.6%.

The company will continue to face problems throughout 2013 with tough competition to its Testim franchise. The drug has strong competition from AbbVie Inc (NYSE:ABBV)’s AndroGel, and Actavis Inc (NYSE:ACT) is also preparing to market its own generic version in mid-2015. These will significantly affect the approximately $250 million in sales the company generates from Testim. Due to these headwinds and no current pipeline catalysts, investors should stay away from Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL).

ArthroCare Corporation (NASDAQ:ARTC) is a medical devices company and is involved in the development and commercialization of surgical products. The company also offers sports medicine products, including ArthroWands, surgical wands, soft-tissue fixation products, etc. Over the last 52 weeks, the stock has fluctuated between $24 and $37. The sell side has a mean target price of $39, which translates into a 16% upside to current valuations.

In the last six months, institutions have sold approximately 2.6 million shares of the company, reducing total ownership by 11%. During the same period, insiders have sold 70,500 shares of ArthroCare Corporation (NASDAQ:ARTC), reducing insider ownership by 21%. One of the primary reasons behind the insiders and institutions selling their stock is the superb 34% run in the last 52 weeks. I believe there are not enough catalysts to take the price higher, and investors should stay away from the company because insiders and institutional investors are already taking profits.

Bottom line

The three companies discussed above have seen insider or institutional selling in the last six months. Moreover, there are no strong catalysts to push up the stock price which significantly limits their upside potential. Therefore, investors should stay away from these stocks until more solid catalysts emerge.

The article 3 Healthcare Stocks to Avoid originally appeared on Fool.com and is written by Mohsin Saeed.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!